Elicio Therapeutics Stock Today

ELTX Stock   3.67  0.01  0.27%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 83

 
High
 
Low
Very High
Elicio Therapeutics is trading at 3.67 as of the 6th of July 2024; that is 0.27% down since the beginning of the trading day. The stock's open price was 3.68. Elicio Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Elicio Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 7th of May 2024 and ending today, the 6th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
5th of February 2021
Category
Healthcare
Classification
Health Care
Elicio Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 10.77 M outstanding shares of which 75.78 K shares are currently shorted by private and institutional investors with about 1.92 trading days to cover. More on Elicio Therapeutics

Moving together with Elicio Stock

  0.61A Agilent Technologies Fiscal Year End 18th of November 2024 PairCorr

Moving against Elicio Stock

  0.55DNLI Denali TherapeuticsPairCorr
  0.5DRRX DurectPairCorr
  0.36VCNX VaccinexPairCorr
  0.32VBIV VBI VaccinesPairCorr

Elicio Stock Highlights

President CEORobert Connelly
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities8.9 M9.8 M
Significantly Down
Slightly volatile
Non Current Liabilities Total5.7 MM
Notably Down
Very volatile
Total Assets20.5 M27.1 M
Way Down
Slightly volatile
Total Current Assets13.2 M16.3 M
Significantly Down
Slightly volatile
Elicio Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Elicio Therapeutics' financial leverage. It provides some insight into what part of Elicio Therapeutics' total assets is financed by creditors.
Liquidity
Elicio Therapeutics currently holds 6.92 M in liabilities. Note, when we think about Elicio Therapeutics' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

62,700
Elicio Therapeutics (ELTX) is traded on NASDAQ Exchange in USA. It is located in 451 D Street, Boston, MA, United States, 02210 and employs 32 people. Elicio Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 39.63 M. Elicio Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 10.77 M outstanding shares of which 75.78 K shares are currently shorted by private and institutional investors with about 1.92 trading days to cover. Elicio Therapeutics generates negative cash flow from operations
Check Elicio Therapeutics Probability Of Bankruptcy
Ownership Allocation
Elicio Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Elicio Ownership Details

Elicio Therapeutics Historical Income Statement

At this time, Elicio Therapeutics' Interest Income is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 1.2 M in 2024, whereas Net Interest Income is likely to drop (720.3 K) in 2024. View More Fundamentals

Elicio Stock Against Markets

Elicio Therapeutics Corporate Management

Joy SeymourVP AffairsProfile
Esther WelkowskySenior DevelopmentProfile
Peter DeMuthChief OfficerProfile
Michael DiVecchiaSenior ResourcesProfile
Megan FiloonSecretary CounselProfile
Brian PiekosChief OfficerProfile

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.